This HTML5 document contains 114 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n9http://www.rxlist.com/cgi/generic3/
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n18http://linked.opendata.cz/resource/AHFS/
n13http://linked.opendata.cz/resource/drugbank/company/
n21http://linked.opendata.cz/resource/drugbank/drug/DB00831/identifier/pubchem-substance/
n31http://linked.opendata.cz/resource/mesh/concept/
foafhttp://xmlns.com/foaf/0.1/
n19http://linked.opendata.cz/resource/drugbank/dosage/
n26http://linked.opendata.cz/resource/drugbank/drug/DB00831/identifier/iuphar/
n33http://linked.opendata.cz/resource/drugbank/mixture/
n7http://linked.opendata.cz/resource/drugbank/drug/DB00831/identifier/drugbank/
n28http://linked.opendata.cz/resource/drugbank/drug/DB00831/identifier/guide-to-pharmacology/
n24http://linked.opendata.cz/resource/drugbank/drug/DB00831/identifier/national-drug-code-directory/
n15http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n6http://linked.opendata.cz/resource/drugbank/drug/DB00831/identifier/chemspider/
n34http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
n11http://linked.opendata.cz/resource/drugbank/drug/DB00831/identifier/chebi/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n20http://linked.opendata.cz/resource/drugbank/medicinal-product/
owlhttp://www.w3.org/2002/07/owl#
n30http://linked.opendata.cz/ontology/mesh/
n3http://linked.opendata.cz/ontology/drugbank/
n16http://www.drugs.com/cdi/
n4http://linked.opendata.cz/resource/drugbank/property/
n29http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/
n35http://linked.opendata.cz/resource/drugbank/drug/DB00831/identifier/wikipedia/
n22http://linked.opendata.cz/resource/drugbank/drug/DB00831/identifier/pharmgkb/
xsdhhttp://www.w3.org/2001/XMLSchema#
n25http://linked.opendata.cz/resource/drugbank/drug/DB00831/identifier/pdb/
n27http://linked.opendata.cz/resource/drugbank/drug/DB00831/identifier/kegg-compound/
n10http://linked.opendata.cz/resource/drugbank/drug/DB00831/identifier/bindingdb/
n23http://linked.opendata.cz/resource/drugbank/drug/DB00831/identifier/pubchem-compound/
n32http://linked.opendata.cz/resource/atc/
n17http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00831
rdf:type
n3:Drug
n3:description
A phenothiazine with actions similar to chlorpromazine. It is used as an antipsychotic and an antiemetic. [PubChem]
n3:dosage
n19:271B483E-363D-11E5-9242-09173F13E4C5 n19:271B4839-363D-11E5-9242-09173F13E4C5 n19:271B483A-363D-11E5-9242-09173F13E4C5 n19:271B483B-363D-11E5-9242-09173F13E4C5 n19:271B483C-363D-11E5-9242-09173F13E4C5 n19:271B483D-363D-11E5-9242-09173F13E4C5 n19:271B483F-363D-11E5-9242-09173F13E4C5 n19:271B4840-363D-11E5-9242-09173F13E4C5 n19:271B4838-363D-11E5-9242-09173F13E4C5
n3:group
approved
n3:halfLife
10-20 hours
n3:indication
For the treatment of anxiety disorders, depressive symptoms secondary to anxiety and agitation.
n3:manufacturer
n13:271B482A-363D-11E5-9242-09173F13E4C5 n13:271B4828-363D-11E5-9242-09173F13E4C5 n13:271B4829-363D-11E5-9242-09173F13E4C5 n13:271B4826-363D-11E5-9242-09173F13E4C5 n13:271B4827-363D-11E5-9242-09173F13E4C5 n13:271B4824-363D-11E5-9242-09173F13E4C5 n13:271B4825-363D-11E5-9242-09173F13E4C5
owl:sameAs
n15:DB00831 n34:DB00831
dcterms:title
Trifluoperazine
adms:identifier
n6:5365 n7:DB00831 n10:50001886 n11:45951 n21:46507961 n22:PA451771 n23:5566 n24:0378-2401-01 n25:TFP n26:214 n27:C07168 n28:214 n35:Trifluoperazine
n3:mechanismOfAction
Trifluoperazine blocks postsynaptic mesolimbic dopaminergic D1 and D2 receptors in the brain; depresses the release of hypothalamic and hypophyseal hormones and is believed to depress the reticular activating system thus affecting basal metabolism, body temperature, wakefulness, vasomotor tone, and emesis.
n3:packager
n13:271B4818-363D-11E5-9242-09173F13E4C5 n13:271B4819-363D-11E5-9242-09173F13E4C5 n13:271B481C-363D-11E5-9242-09173F13E4C5 n13:271B481D-363D-11E5-9242-09173F13E4C5 n13:271B481A-363D-11E5-9242-09173F13E4C5 n13:271B481B-363D-11E5-9242-09173F13E4C5 n13:271B4820-363D-11E5-9242-09173F13E4C5 n13:271B4821-363D-11E5-9242-09173F13E4C5 n13:271B481E-363D-11E5-9242-09173F13E4C5 n13:271B481F-363D-11E5-9242-09173F13E4C5 n13:271B4822-363D-11E5-9242-09173F13E4C5 n13:271B4823-363D-11E5-9242-09173F13E4C5
n3:synonym
10-[3-(4-Methyl-1-piperazinyl)propyl]-2-(trifluoromethyl)-10H-phenothiazine Trifluoroperazine Trifluoperazinum Trifluoperazina Trifluperazine 10-[3-(4-METHYL-piperazin-1-yl)-propyl]-2-trifluoromethyl-10H-phenothiazine Trifluoromethyl-10-(3'-(1-methyl-4-piperazinyl)propyl)phenothiazine Trifluoperazine
n3:toxicity
Symptoms of overdose include agitation, coma, convulsions, difficulty breathing, difficulty swallowing, dry mouth, extreme sleepiness, fever, intestinal blockage, irregular heart rate, low blood pressure, and restlessness.
n17:hasAHFSCode
n18:28-16-08-24
n3:mixture
n33:271B4816-363D-11E5-9242-09173F13E4C5 n33:271B4817-363D-11E5-9242-09173F13E4C5 n33:271B4814-363D-11E5-9242-09173F13E4C5 n33:271B4815-363D-11E5-9242-09173F13E4C5
n3:salt
n30:hasConcept
n31:M0021955
foaf:page
n9:trifluo.htm n16:trifluoperazine.html n29:tri1412.shtml
n3:IUPAC-Name
n4:271B4845-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B484B-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B484A-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B4847-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B4848-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B4849-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B485A-363D-11E5-9242-09173F13E4C5 n4:271B4843-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B485B-363D-11E5-9242-09173F13E4C5 n4:271B4844-363D-11E5-9242-09173F13E4C5 n4:271B4841-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B485C-363D-11E5-9242-09173F13E4C5 n4:271B4842-363D-11E5-9242-09173F13E4C5
n17:hasATCCode
n32:N05AB06
n3:H-Bond-Acceptor-Count
n4:271B4851-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B4852-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B484C-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B484D-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B484F-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B484E-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B4850-363D-11E5-9242-09173F13E4C5
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
117-89-5
n3:category
n3:containedIn
n20:271B482D-363D-11E5-9242-09173F13E4C5 n20:271B482E-363D-11E5-9242-09173F13E4C5 n20:271B482B-363D-11E5-9242-09173F13E4C5 n20:271B482C-363D-11E5-9242-09173F13E4C5 n20:271B4831-363D-11E5-9242-09173F13E4C5 n20:271B4832-363D-11E5-9242-09173F13E4C5 n20:271B482F-363D-11E5-9242-09173F13E4C5 n20:271B4830-363D-11E5-9242-09173F13E4C5 n20:271B4835-363D-11E5-9242-09173F13E4C5 n20:271B4836-363D-11E5-9242-09173F13E4C5 n20:271B4833-363D-11E5-9242-09173F13E4C5 n20:271B4834-363D-11E5-9242-09173F13E4C5 n20:271B4837-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n4:271B4856-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B4858-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B4859-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B4855-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B4854-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B4857-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B4846-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B4853-363D-11E5-9242-09173F13E4C5